· · · · · · · · · · · · · · · · · · ·	Application No.	Applicant(s)
Interview Summary	09/451,666	ITO ET AL.
	Examiner	Art Unit
	BJ Forman	1634
All participants (applicant, applicant's representative, PTO personnel):		
(1) <u>BJ Forman</u> .	(3)	
(2) <u>Gregory Einhorn</u> .	(4)	
Date of Interview: <u>13 November 2002</u> .		
Type: a)⊠ Telephonic b)□ Video Conference c)□ Personal [copy given to: 1)□ applicant 2)□ applicant's representative]		
Exhibit shown or demonstration conducted: d) Yes e) No. If Yes, brief description:		
Claim(s) discussed: 7 and 24-26		
Identification of prior art discussed:		
Agreement with respect to the claims f)☐ was reached. g)☑ was not reached. h)☐ N/A.		
Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: <u>See Continuation Sheet</u> .		
(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)		
i) ☐ It is not necessary for applicant to provide a checked).		
Unless the paragraph above has been checked, THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.		
		/
Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.	Examiner's s	ignature, if required

U.S. Patent and Trademark Office PTO-413 (Rev. 03- 98) Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: Mr. Einhorn discussed the novel concepts of the invention as being depositing binding agent and probe locally onto underivatized supports. The examiner stated that the claimed "binding agent" encompasses numerous agents including complementary nucleic acids and biotin which are disclosed in the prior art. The examiner further stated that support for an "underivatized" surface is not provided in the specification. The examiner suggested that the claims be amended to define the invention as described in the specification e.g. limit the binding agent to those recited in Claim 7. The examiner stated that such an amendment may overcome the prior art.